Adaptive Biotechnologies (NASDAQ:ADPT) Sees Unusually-High Trading Volume – Here’s Why

Shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) saw unusually-high trading volume on Wednesday . Approximately 3,589,028 shares traded hands during mid-day trading, an increase of 76% from the previous session’s volume of 2,044,294 shares.The stock last traded at $17.2220 and had previously closed at $17.22.

Analyst Upgrades and Downgrades

ADPT has been the subject of a number of recent research reports. Morgan Stanley reduced their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, May 12th. JPMorgan Chase & Co. reduced their price objective on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. TD Cowen boosted their price objective on shares of Adaptive Biotechnologies from $19.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Guggenheim reissued a “buy” rating and issued a $21.00 price objective on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Finally, Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research note on Saturday, March 7th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $19.57.

Adaptive Biotechnologies Stock Down 2.3%

The business has a 50-day moving average price of $14.67 and a 200-day moving average price of $15.61. The firm has a market capitalization of $2.69 billion, a price-to-earnings ratio of -51.03 and a beta of 2.16.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.03. The business had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.The business’s quarterly revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.20) earnings per share. On average, equities research analysts forecast that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current year.

Insider Transactions at Adaptive Biotechnologies

In other news, insider Francis Lo sold 39,741 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $17.49, for a total transaction of $695,070.09. Following the sale, the insider directly owned 250,934 shares of the company’s stock, valued at $4,388,835.66. The trade was a 13.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Julie Rubinstein sold 30,941 shares of the business’s stock in a transaction on Wednesday, April 8th. The shares were sold at an average price of $14.83, for a total transaction of $458,855.03. Following the sale, the chief operating officer directly owned 434,188 shares in the company, valued at $6,439,008.04. This trade represents a 6.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 483,534 shares of company stock valued at $7,097,885. Corporate insiders own 5.70% of the company’s stock.

Institutional Investors Weigh In On Adaptive Biotechnologies

A number of large investors have recently made changes to their positions in ADPT. Westfield Capital Management Co. LP purchased a new stake in shares of Adaptive Biotechnologies during the fourth quarter valued at $65,942,000. Price T Rowe Associates Inc. MD grew its holdings in shares of Adaptive Biotechnologies by 303.4% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,387,361 shares of the company’s stock valued at $71,252,000 after buying an additional 3,299,635 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Adaptive Biotechnologies by 84.3% during the third quarter. Ameriprise Financial Inc. now owns 5,971,706 shares of the company’s stock valued at $89,337,000 after buying an additional 2,731,648 shares during the last quarter. Invesco Ltd. grew its holdings in shares of Adaptive Biotechnologies by 248.8% during the fourth quarter. Invesco Ltd. now owns 3,107,653 shares of the company’s stock valued at $50,468,000 after buying an additional 2,216,595 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its holdings in shares of Adaptive Biotechnologies by 544.0% during the third quarter. Arrowstreet Capital Limited Partnership now owns 2,441,402 shares of the company’s stock valued at $36,523,000 after buying an additional 2,062,282 shares during the last quarter. 99.17% of the stock is owned by hedge funds and other institutional investors.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.